retatrutide phase 2 trial results obesity Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide just delivered the first
Description
RCT: Randomized Controlled Trial
Freemantle N, Mamdani M, Vilsbll T, Kongs JH, Kvist K, Bain SC

The effects of aerobic exercise training on serum osteocalcin, adipocytokines and insulin resistance on obese young males

Legion Peptides maintains strict analytical verification, transparent documentation, controlled sourcing, and research-focused manufacturing standards

SEMA GLP-1 is produced in an FDA-registered laboratory in the USA and ships sealed in discreet packaging